bluuebunny/crossref_metadata_2025_split huggingface dataset:
Around the Corner to Better Health: A Milwaukee Corner Store Initiative
Authors: Young Staci , DeNomie Melissa , Sabir JoAnne , Gass Eric , Tobin Jessie 
Published: November 2017

Purpose: To discuss successes and challenges of a collaborative pilot project to increase healthy food availability in corner stores in Milwaukee, Wisconsin. The Lindsay Heights Healthy Corner Store Initiative aimed to help corner stores sell high-quality produce by increasing supply of healthy foods and funding minor store upgrades to facilitate change. Design: Evaluation research. Setting: Milwaukee, Wisconsin. Participants: Corner stores; youth and adult community members. Intervention: (1) Supporting businesses in purchasing equipment to stock fresh produce, (2) connecting stores with produce sources, and (3) community outreach and marketing. Measures: Partnership capacity, youth engagement in food justice, and community members’ usage of corner stores. Analysis: Qualitative analysis; descriptive statistics. Results: Storeowners reported more sold produce items per week and increased noticeable fresh produce upon entrance into the store. There was increased or improved store redesign, fresh produce signage, in-store cooking demonstrations, and small business development resources. Conclusion: Youth learned about new vegetables, increased kitchen skills and proper food storage, and the effects of obesity on overall health. Similar interventions must address infrastructure costs, cooperation with property owners, and local policies and regulations affecting business practices.
The Impact of Cirrhosis and Prescription Medications on QTc Interval Before and After Liver Transplantation
Authors: Santeusanio Andrew D. , Dunsky Kevin G. , Pan Stephanie , Schiano Thomas D. 
Published: November 2017

Background: Higher rates of corrected QT (QTc) prolongation have been reported in patients with cirrhosis. The impact of liver transplantation and prescription medications on the natural history of QTc prolongation has yet to be well characterized. Methods: This was a single-center review of patients receiving (group 1) or listed for (group 2) a liver transplant during 2014. Patients in group 1 were followed prospectively from the date of transplantation to assess rates of QTc normalization posttransplant. In group 2, patients were evaluated from the date of listing up until December 2015 to assess the prevalence of QTc prolongation among liver transplant candidates. Results: In group 1, 22 (75.9%) patients with QTc intervals >460 milliseconds at the time of transplant established normal baseline QTc intervals following transplantation. The median time to this QTc normalization was 17 days. In group 2, 30 (16.9%) patients had at least 1 documented QTc interval >500 milliseconds with prevalence rates of 42.9%, 19.0%, and 10.2% in patients with natural model of end-stage liver disease scores of >30, 16 to 30, and <16, respectively ( P < .01). Overall, 49.4% of patients in group 1 and 47.5% of patients in group 2 were prescribed QTc prolonging medications. Conclusion: QTc prolongation will resolve following transplantation in the majority of patients and generally occurs within the first several weeks. Among the listed liver transplant candidates, higher rates of clinically significant QTc prolongation may be observed in patients with more severe underlying cirrhosis. QTc prolonging medications are commonly prescribed in this population and warrant monitoring following initiation.
Application of Breast Ultrasound Elastography to Differentiate Intracapsular Collection from Silicone-Induced Granuloma of Breast Implant Capsule Complementarily to Contrast-Enhanced Breast Magnetic Resonance Imaging
Authors: de Faria Castro Fleury Eduardo , Gianini Ana Claudia , Ayres Veronica , Ramalho Luciana C , Roveda Decio , de Oliveira Vilmar Marques 
Published: November 2017

Background: To determine whether there is correlation between magnetic resonance imaging (MRI) findings and breast elastography to differentiate seroma/hematoma from silicone-induced granuloma of breast implant capsule (SIGBIC). Methods: Prospective study of 99 patients with breast implants submitted to breast MRI during the period from February 1 to May 1, 2017. Patients who present MRI findings of seroma/hematoma or SIGBIC were submitted to a complementary ultrasound elastography study to evaluate the correlation of the results. The criteria adopted for the diagnosis of granuloma by MRI were heterogeneous hypersignal in the T2-weighted sequences, late contrast enhancement, and black drop sign. Lesions that did not enhance after the use of contrast were considered as seroma/hematoma. By elastography, the results were considered positive for granuloma when presented as hard lesions, whereas seroma/hematoma presented as soft lesions. Results: Of the 99 patients evaluated, 15 were included in the study. Of the 15 patients, 9 had solid intracapsular MRI masses, whereas 6 presented collections without contrast enhancement. The complementary elastography study showed correlation with MRI results in all cases of SIGBIC and seroma/hematoma, being elastography able to differentiate lesions from solid to cystic. Conclusions: Elastography of intracapsular masses in breast implants presented results compatible with those found by MRI to differentiate solid lesions from collections.
A Survey of 24,000 Students Aged 13–15 Years in India: Global Youth Tobacco Survey 2006 and 2009
Authors: Gajalakshmi V. , Kanimozhi C.V. 
Published: November 2017

Background Students aged 13–15 years in Grades 8–10 have been surveyed in the year 2006 and in 2009 to monitor the prevalences of smoking and smokeless tobacco use and to assess their attitudes, knowledge and behaviors towards tobacco use and its health impact. Methods The Global Youth Tobacco Survey is a cross sectional survey that uses a two-stage cluster sample design to get a representative sample of schools and students for the study. In India, a total of 12 086 students in the year 2006 and 11 768 in 2009 were surveyed. Results About 14% (13.7% in 2006 and 14.6% in 2009) of students use tobacco (smoking/smokeless tobacco). The prevalence of smoking among boys is about three times that of girls in both the surveys. The prevalence of smokeless tobacco among girls is twice that of smoking tobacco in both the surveys. In the 2009 survey comparing with the 2006, the percentage of students who initiated bidi smoking before 10 years of age is significantly higher in boys (2006: 26.0% and 2009:45.4%); the percentage of never smokers likely to initiate smoking in the following year is significantly lower in girls (2006: 16.0% and 2009: 10.8%); the percentage of students exposed to smoke from parents is significantly lower (2006: Boys-38.3%, Girls-30.7% and 2009: Boys-29.3%, Girls-22.4%); the percentage of students who reported that they were taught about the dangers of smoking during the school year is higher; and, ever smokers received help or advice to help stop smoking is significantly higher (2009: 19.5% and 2006: 4.4%). The percentage of students who saw any advertisements for tobacco, the percentage of students offered free cigarettes by a cigarette company representative or their access/availability to smoking tobacco and the changes observed in the prevalences of tobacco use among students in 2009 is not significantly different from 2006. Conclusions No significant difference is seen in the prevalence of tobacco use among students between the 2006 and 2009 surveys. The percentage of boys who initiated bidi smoking before age 10 is statistically higher in 2009 compared to 2006. There is a need to strengthen enforcement of policies already in place as well as focus on expansion into additional program efforts.
Gene expression and risk of leukemic transformation in myelodysplasia
Authors: Shiozawa Yusuke , Malcovati Luca , Gallì Anna , Pellagatti Andrea , Karimi Mohsen , Sato-Otsubo Aiko , Sato Yusuke , Suzuki Hiromichi , Yoshizato Tetsuichi , Yoshida Kenichi , Shiraishi Yuichi , Chiba Kenichi , Makishima Hideki , Boultwood Jacqueline , Hellström-Lindberg Eva , Miyano Satoru , Cazzola Mario , Ogawa Seishi 
Published: November 2017

Key Points
Through a comprehensive transcriptomic analysis, we discovered 2 major subgroups of myelodysplasia defined by gene expression profiles. The gene expression–based subgroups had independent prognostic value, which was validated in an external cohort.
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
Authors: Harris Marianne , Ganase Bruce , Watson Birgit , Harrigan P. Richard , Montaner Julio S. G. , Hull Mark W. 
Published: November 2017

Abstract
Background
As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and pharmacokinetics of once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) with darunavir.

Methods
A single arm, open-label 48-week study was conducted of regimen simplification to E/C/F/TDF plus darunavir 800 mg daily from stable therapy including two nucleoside/nucleotide reverse transcriptase inhibitors, a ritonavir-boosted protease inhibitor, and an integrase inhibitor. Participants had plasma HIV viral load consistently < 200 copies/mL for ≥ 6 months, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min, and no genotypic resistance to major components of the study regimen. Plasma viral load was measured at weeks 2 and 4, then every 4 weeks throughout the study. Safety laboratory assessments were conducted at baseline and at weeks 12, 24, 36, and 48. Antiretroviral drug concentrations were measured at baseline and once ≥ 2 weeks after the regimen change.

Results
Ten HIV-infected adults (8 male and 2 female; median age 50.5 years) were enrolled. All maintained virologic suppression on the new regimen for 48 weeks. One subject experienced a decrease in eGFR from 62 mL/min at baseline to 52 mL/min at week 12; study medications were continued and his eGFR remained stable (50–59 mL/min) thereafter. No subjects discontinued study medications for renal function changes or other adverse events. Darunavir trough concentration were lower on the new regimen than on darunavir/ritonavir 800/100 mg (n = 5; p < 0.05).

Conclusions
Despite low darunavir trough concentrations, treatment simplification to a two-pill, once-daily regimen of E/C/F/TDF plus darunavir was safe and effective for 48 weeks among 10 selected treatment-experienced HIV-infected patients.
Trial registration The study protocol was registered with ClinicalTrials.gov (NCT02199613) on July 22, 2014
Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence
Authors: Butow Phyllis N. , Turner Jane , Gilchrist Jemma , Sharpe Louise , Smith Allan Ben , Fardell Joanna E. , Tesson Stephanie , O’Connell Rachel , Girgis Afaf , Gebski Val J. , Asher Rebecca , Mihalopoulos Cathrine , Bell Melanie L. , Zola Karina Grunewald , Beith Jane , Thewes Belinda 
Published: November 2017

Purpose Fear of cancer recurrence (FCR) is prevalent, distressing, and long lasting. This study evaluated the impact of a theoretically/empirically based intervention (ConquerFear) on FCR. Methods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age > 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening. Participants were randomly assigned at a one-to-one ratio to either five face-to-face sessions of ConquerFear (attention training, metacognitions, acceptance/mindfulness, screening behavior, and values-based goal setting) or an attention control (Taking-it-Easy relaxation therapy). Participants completed questionnaires at baseline (T0), immediately post-therapy (T1), and 3 (T2) and 6 months (T3) later. The primary outcome was FCRI total score. Results Of 704 potentially eligible survivors from 17 sites and two online databases, 533 were contactable, of whom 222 (42%) consented; 121 were randomly assigned to intervention and 101 to control. Study arms were equivalent at baseline on all measured characteristics. ConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P < .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total). Differences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3. Conclusion This randomized trial demonstrated efficacy of ConquerFear compared with attention control (Taking-it-Easy) in reduction of FCRI total scores immediately post-therapy and 3 and 6 months later and in many secondary outcomes immediately post-therapy. Cancer-specific distress (total) remained more improved at 3- and 6-month follow-up.
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
Authors: Luminari Stefano , Ferrari Angela , Manni Martina , Dondi Alessandra , Chiarenza Annalisa , Merli Francesco , Rusconi Chiara , Tarantino Vittoria , Tucci Alessandra , Vitolo Umberto , Kovalchuk Sofia , Angelucci Emanuele , Pulsoni Alessandro , Arcaini Luca , Angrilli Francesco , Gaidano Gianluca , Stelitano Caterina , Bertoldero Giovanni , Cascavilla Nicola , Salvi Flavia , Ferreri Andrés J.M. , Vallisa Daniele , Marcheselli Luigi , Federico Massimo 
Published: November 2017

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Authors: Frenel Jean-Sebastien , Le Tourneau Christophe , O’Neil Bert , Ott Patrick A. , Piha-Paul Sarina A. , Gomez-Roca Carlos , van Brummelen Emilie M.J. , Rugo Hope S. , Thomas Shari , Saraf Sanatan , Rangwala Reshma , Varga Andrea 
Published: November 2017

Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, by investigator review. Safety was a secondary end point. Results Twenty-four patients were enrolled in the cervical cancer cohort. The median age was 42 years (range, 26 to 62 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received two or more lines of therapy, including bevacizumab (10 of 24 patients), for advanced disease. At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 months). Overall response rate was 17% (95% CI, 5% to 37%); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable disease. Median duration of response for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months). Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in ≥ 10% of patients. Five patients experienced grade 3 treatment-related AEs. No grade 4 treatment-related AEs or deaths were observed. Conclusion In patients with programmed death ligand 1–positive advanced cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consistent with that seen in other tumor types.
Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer
Authors: Chow Eric J. , Chen Yan , Hudson Melissa M. , Feijen Elizabeth A.M. , Kremer Leontien C. , Border William L. , Green Daniel M. , Meacham Lillian R. , Mulrooney Daniel A. , Ness Kirsten K. , Oeffinger Kevin C. , Ronckers Cécile M. , Sklar Charles A. , Stovall Marilyn , van der Pal Helena J. , van Dijk Irma W.E.M. , van Leeuwen Flora E. , Weathers Rita E. , Robison Leslie L. , Armstrong Gregory T. , Yasui Yutaka 
Published: November 2017

PurposeWe aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of childhood cancer.Patients and MethodsParticipants in the Childhood Cancer Survivor Study (CCSS; n = 13,060) were observed through age 50 years for the development of ischemic heart disease and stroke. Siblings (n = 4,023) established the baseline population risk. Piecewise exponential models with backward selection estimated the relationships between potential predictors and each outcome. The St Jude Lifetime Cohort Study (n = 1,842) and the Emma Children’s Hospital cohort (n = 1,362) were used to validate the CCSS models.ResultsIschemic heart disease and stroke occurred in 265 and 295 CCSS participants, respectively. Risk scores based on a standard prediction model that included sex, chemotherapy, and radiotherapy (cranial, neck, and chest) exposures achieved an area under the curve and concordance statistic of 0.70 and 0.70 for ischemic heart disease and 0.63 and 0.66 for stroke, respectively. Validation cohort area under the curve and concordance statistics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke. Risk scores were collapsed to form statistically distinct low-, moderate-, and high-risk groups. The cumulative incidences at age 50 years among CCSS low-risk groups were < 5%, compared with approximately 20% for high-risk groups ( P < .001); cumulative incidence was only 1% for siblings ( P < .001 v low-risk survivors).ConclusionInformation available to clinicians soon after completion of childhood cancer therapy can predict individual risk for subsequent ischemic heart disease and stroke with reasonable accuracy and discrimination through age 50 years. These models provide a framework on which to base future screening strategies and interventions.
High-Fat, High-Sugar Diet Disrupts the Preovulatory Hormone Surge and Induces Cystic Ovaries in Cycling Female Rats
Authors: Volk Katrina M , Pogrebna Veronika V , Roberts Jackson A , Zachry Jennifer E , Blythe Sarah N , Toporikova Natalia 
Published: November 2017

Abstract
Diet-induced obesity has been associated with various metabolic and reproductive disorders, including polycystic ovary syndrome. However, the mechanisms by which obesity influences the reproductive system are still not fully known. Studies have suggested that impairments in hormone signaling are associated with the development of symptoms such as acyclicity and ovarian cysts. However, these studies have often failed to address how these hormonal changes arise and how they might contribute to the progression of reproductive diseases. In the present study, we used a high-fat, high-sugar (HFHS) diet to induce obesity in a female rodent model to determine the changes in critical reproductive hormones that might contribute to the development of irregular estrous cycling and reproductive cycle termination. The HFHS animals exhibited impaired estradiol, progesterone (P4), and luteinizing hormone (LH) surges before ovulation. The HFHS diet also resulted in altered basal levels of testosterone (T) and LH. Furthermore, alterations in the basal P4/T ratio correlated strongly with ovarian cyst formation in HFHS rats. Thus, this model provides a method to assess the underlying etiology of obesity-related reproductive dysfunction and to examine an acyclic reproductive phenotype as it develops.
CREB3L1-mediated functional and structural adaptation of the secretory pathway in hormone-stimulated thyroid cells
Authors: García Iris A. , Torres Demichelis Vanina , Viale Diego L. , Di Giusto Pablo , Ezhova Yulia , Polishchuk Roman S. , Sampieri Luciana , Martinez Hernán , Sztul Elizabeth , Alvarez Cecilia 
Published: November 2017

ABSTRACT
Many secretory cells increase the synthesis and secretion of cargo proteins in response to specific stimuli. How cells couple increased cargo load with a coordinate rise in secretory capacity to ensure efficient transport is not well understood. We used thyroid cells stimulated with thyrotropin (TSH) to demonstrate a coordinate increase in the production of thyroid-specific cargo proteins and ER–Golgi transport factors, and a parallel expansion of the Golgi complex. TSH also increased expression of the CREB3L1 transcription factor, which alone caused amplified transport factor levels and Golgi enlargement. Furthermore, CREB3L1 potentiated the TSH-induced increase in Golgi volume. A dominant-negative CREB3L1 construct hampered the ability of TSH to induce Golgi expansion, implying that this transcription factor contributes to Golgi expansion. Our findings support a model in which CREB3L1 acts as a downstream effector of TSH to regulate the expression of cargo proteins, and simultaneously increases the synthesis of transport factors and the expansion of the Golgi to synchronize the rise in cargo load with the amplified capacity of the secretory pathway.